Alnylam Interview: RNAi Leader Expands Into NASH, CNS And Eye Diseases

Buoyed By $1bn Regeneron Alliance

Alnylam
Alnylam's Boston, MA headquarters. It will take another 5-10 years for Alnylam to enter biopharma's 'big league' - but it has already put RNAi on the map • Source: Photo Courtesy of BioMed Realty, L.P. All Rights Reserved
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapy Areas